Investors

Corporate Background

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in auto-immune and oncology disease indications. The company’s drug products use proprietary recombinant human alpha fetoprotein (AFP) technology with unique immuno-oncology properties.

In Immunology the company is ready to enter Phase II clinical trials in Myasthenia Gravis (MG) (Orphan Drug Designation from FDA) followed by Phase II clinical trials in multiple sclerosis. ACT-101 (AFP) has been shown to be as safe as placebo in clinical trials in over 300 patients.

In Oncology AFP can deliver chemotherapy on a targeted basis to provide greater efficacy with significantly reduced toxicity.

Celgene, one of the world’s largest biotechnology companies owns a 12% equity stake in ACT.

The company has a significantly mitigated risk profile in every area of development and an expedited clinical development path.

Game Changer

Immunology

It is well-known that autoimmune diseases in women typically go into remission during pregnancy and there is a strong correlation between the level of AFP in mother’s blood and the decrease in the symptoms of her disease. In preclinical models of MG, AFP was able to block the MG antibodies from attacking the ACh receptors on the muscle.

Oncology

In Oncology AFP is a carrier protein known for transporting nutrients to rapidly growing fetal cells and also acts as an immune regulatory protein involved in the protection of the fetus from attack by the mother’s immune system. Only trace amounts of the protein are found following the fetal stage but receptors for AFP show up again on almost all solid and liquid cancer cells. The company uses AFP to deliver a chemotherapy payload to selectively kill cancer cells. Lower toxicity of this targeted approach offers the ability to treat the patient more frequently until the patient is cancer free.

Pipeline

ACT has several lead products that include non-covalently bound chemotherapy (paclitaxel, thapsigargin) and chemically linked chemotherapy such as maytansine. In addition to proven efficacy and known safety profile of generic chemotherapy drugs, AFP itself has been proven as safe as placebo in over 300 patients in Phase I and II clinical studies. ACT’s products are being developed as a treatment for multiple cancer indications as almost all cancer cells (>80%) express AFP receptors and healthy cells do not.

Therapy Indication Partners Discovery Pre-Clinical Phase I Phase II
ACT-101
(AFP)
Autoimmune
Inflammatory Bowel Disease (Crohn’s/Colitis)
 
Myasthenia Gravis (muscle weakness)
 
Hashimoto Disease
 
Multiple Sclerosis, Others
 
ACT-901
(AFP + paclitaxel)
Targeted Oncology
Solid and liquid tumors
Collaboration University Health Network
Princess Margaret Cancer Center
 
ACT-902
(AFP + thapsigargin)
Targeted Oncology
Solid and liquid tumors
Collaboration University Health Network
 
ACT-903
(AFP + linker + maytansine)
Targeted Oncology
Solid and liquid tumors
Collaboration Polytherics (Abzena) U.K.
 

Subscribe To Updates

Fill out this form to receive the latest updates, news, and press releases from Alpha Cancer Technologies.

You can unsubscribe at any time by clicking on the unsubscribe link at the bottom of our emails.

Alpha Cancer Technologies
www.alpha-cancer.com
200-101 College St.
Toronto, Ontario, M5G 1L7
Canada